zika
viru
zikv
humanpathogen
flaviviru
recent
emerg
global
public
health
threat
zikv
infect
may
associ
congenit
malform
infect
fetus
sever
neurolog
system
complic
infect
adult
current
limit
treatment
option
zikv
infect
celecoxib
deriv
cellular
kinas
inhibitor
broadspectrum
antivir
activ
studi
investig
antivir
activ
mechan
zikv
evalu
vitro
antizikv
activ
use
cell
protect
viru
yield
reduct
assay
multipl
clinic
relev
cell
line
vivo
treatment
effect
lethal
mous
model
use
type
interferon
receptordefici
mice
inhibit
zikv
strain
belong
african
asianamerican
lineag
andor
neuron
cell
ic
zikv
consist
cell
zikvinfect
mice
treat
intraperiton
oral
administ
significantli
higher
surviv
rate
vs
p
less
bodi
weight
loss
lower
blood
tissu
zikv
rna
load
untreat
control
mice
antizikv
effect
like
result
downregul
pathway
clinic
trial
use
clinic
avail
broadspectrum
empir
treatment
consid
especi
patient
resid
return
area
endem
zikv
arbovir
infect
present
acut
undifferenti
febril
ill
global
climat
chang
continu
reshap
geograph
distribut
human
anim
vector
microb
allow
mix
occur
unprecedentedli
high
frequenc
chan
et
al
numer
emerg
pathogen
past
decad
avian
influenza
virus
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
coronavirus
ebola
viru
virus
caus
hemorrhag
fever
macneil
rollin
marsh
wang
et
al
et
al
latest
emerg
viral
epidem
declar
intern
health
emerg
one
caus
zika
viru
zikv
musso
gubler
zikv
humanpathogen
flaviviru
neglect
recent
found
zikv
infect
may
associ
sever
clinic
complic
includ
congenit
microcephali
anomali
neurolog
complic
guillainbarr
syndrom
meningoenceph
ophthalmolog
defect
auditori
impair
rare
multiorgan
involv
death
chan
et
al
musso
gubler
zikv
infect
similar
emerg
viral
infect
may
nonspecif
clinic
manifest
earli
phase
diseas
chan
et
al
duffi
et
al
exampl
zikv
infect
may
manifest
acut
febril
ill
rash
system
upset
may
indistinguish
dengu
fever
viral
hemorrhag
fever
syndrom
chan
et
al
duffi
et
al
moreov
zikv
may
cocircul
virus
geograph
region
coinfect
patient
musso
gubler
case
emerg
viral
infect
current
limit
treatment
option
proven
effect
safe
zikv
infect
thu
broadspectrum
agent
use
empir
treatment
patient
acut
undifferenti
febril
ill
diagnosi
confirm
laboratori
test
urgent
need
import
group
drug
broadspectrum
antivir
activ
agent
target
host
pathway
enzym
involv
replic
cycl
differ
virus
zumla
et
al
exampl
host
cellular
kinas
increasingli
implic
pathogenesi
viral
infect
may
exploit
virus
facilit
replic
chu
yang
linero
scolaro
saeed
et
al
urata
et
al
flavivirus
phosphatidylinositol
kinaseprotein
kinas
b
pathway
shown
enhanc
viral
replic
counteract
virusinduc
cellular
apoptosi
lee
et
al
tsai
et
al
fdaapprov
investig
new
drug
ind
compound
celecoxib
deriv
kinas
inhibitor
inhibit
cyclooxygenas
activ
instead
downregul
pathway
involv
multipl
cell
signal
pathway
chen
et
al
mohr
et
al
evalu
phase
clinic
trial
anticanc
agent
adult
patient
advanc
recurr
solid
tumor
lymphoma
clinic
trial
registr
addit
anticanc
effect
exhibit
vitro
andor
vivo
antimicrobi
activ
wide
rang
pathogen
microb
includ
intracellular
bacteria
salmonella
enterica
francisella
tularensi
fungi
candida
albican
nonalbican
candida
sp
cryptococcu
neoforman
fusarium
sp
mucoral
blastomyc
dermatitidi
histoplasma
capsulatum
coccidioid
immiti
parasit
leishmania
donovani
virus
lassa
marburg
ebola
virus
chiu
et
al
chiu
et
al
collier
et
al
koselni
et
al
mohr
et
al
importantli
european
commiss
design
orphan
drug
could
use
clinic
combin
antiinfect
agent
treatment
cryptococcosi
fluconazol
tularemia
gentamicin
booth
et
al
clinic
experi
make
clinic
readili
avail
drug
emerg
infecti
diseas
lack
effect
treatment
option
recent
report
vitro
vivo
antivir
activ
dengu
viru
denv
anoth
flaviviru
close
relat
emerg
zikv
chen
et
al
hassandarvish
et
al
therefor
hypothes
broadspectrum
hosttarget
antivir
drug
may
also
exhibit
inhibitori
activ
zikv
studi
evalu
vitro
vivo
antivir
activ
zikv
investig
mechan
antizikv
activ
anim
experi
approv
committe
use
live
anim
teach
research
univers
hong
kong
perform
accord
establish
safeti
protocol
biosafeti
laboratori
depart
microbiolog
univers
hong
kong
viru
strain
cell
line
drug
compound
zikvpr
puerto
rico
strain
isol
patient
recent
south
american
epidem
kindli
provid
brandi
russel
barbara
johnson
center
diseas
control
prevent
usa
zikvgd
isol
chines
patient
return
guangdong
infect
zikv
travel
america
kindli
provid
georg
f
gao
chines
academi
scienc
china
zikvu
uganda
strain
isol
nonhuman
primat
uganda
kindli
provid
tatjana
univers
ljubljana
slovenia
european
viru
archiv
viru
strain
cultur
titrat
previous
describ
chan
et
al
yuan
et
al
cell
line
obtain
american
type
cultur
collect
cell
line
obtain
jcrb
cell
bank
okayama
univers
japan
chan
et
al
akt
inhibitor
akt
inhibitor
viii
purchas
invivogen
sandiego
ca
usa
millipor
burlington
usa
respect
ontargetplu
human
akt
sirna
ontargetplu
nontarget
sirna
purchas
dharmacon
lafayett
co
usa
effect
cytotox
concentr
cc
cell
cell
protect
effect
zikv
infect
cell
line
determin
celltiterglo
luminesc
cell
viabil
assay
promegacorpor
madison
wi
usa
accord
manufactur
instruct
previous
describ
mohr
et
al
determin
cc
treatment
without
zikv
infect
cell
treat
differ
concentr
h
cell
protect
effect
cell
infect
zikvpr
multipl
infect
moi
h
treat
dimethyl
sulfoxid
dmso
ie
h
h
reconstitut
celltiterglo
reagent
ad
cell
accord
manufactur
instruct
luminesc
signal
detect
victor
multilabel
reader
perkinelm
accord
manufactur
instruct
antivir
activ
zikv
evalu
cell
cultur
previous
describ
chan
et
al
yuan
et
al
briefli
zikvinfect
cell
moi
treat
differ
concentr
dmso
cell
cultur
supernat
collect
h
postinocul
hpi
follow
total
nucleic
acid
extract
quantit
revers
transcriptionpcr
qrtpcr
previous
describ
chan
et
al
chan
et
al
addit
cell
inocul
high
moi
zikv
moi
h
viru
inoculum
remov
cell
wash
cultur
fresh
medium
contain
differ
concentr
dmso
hpi
supernat
collect
subsequ
appli
viru
titrat
use
qrtpcr
plaqu
assay
half
maxim
inhibitori
concentr
ic
calcul
use
sigma
plot
excel
addin
previous
describ
chan
et
al
chan
et
al
chan
et
al
thoroughli
compar
differ
percentag
cell
infect
zikv
versu
untreat
sampl
flow
cytometri
immunostain
perform
previous
describ
slight
modif
chu
et
al
chu
et
al
briefli
cell
infect
zikvpr
moi
mockinfect
h
h
inoculum
remov
cell
wash
phosphatebuff
salin
pb
dulbecco
modifi
eagl
medium
dmem
dmso
sigmaaldrich
stloui
mo
usa
ad
cell
hpi
cell
detach
use
mm
ethylenediaminetetraacet
acid
edta
pb
fix
paraformaldehyd
immunostain
cell
first
permeabil
triton
pb
block
fetal
bovin
serum
fb
pb
zikv
detect
mous
primari
antibodi
abcam
cambridg
unit
kingdom
mous
antipanflaviviru
primari
antibodi
millipor
alexa
fluor
goat
antimous
immunoglobulin
igg
invitrogen
carlsbad
ca
usa
secondari
antibodi
flow
cytometri
perform
use
bd
facscanto
ii
flow
cytomet
bd
bioscienc
san
jose
ca
usa
data
analyz
use
flowjo
vx
tree
star
fig
inhibit
replic
zikv
strain
belong
asianamerican
african
lineag
cell
dosedepend
reduct
zikv
rna
load
observ
h
zikvpr
zikvgd
zikvu
inocul
moi
cell
experi
perform
triplic
three
independ
experi
confirm
denot
p
denot
p
denot
p
compar
dmso
control
group
student
ttest
data
present
mean
valu
standard
deviat
error
bar
abbrevi
zikv
zika
viru
cell
lyse
radioimmunoprecipit
assay
ripa
lysi
buffer
thermo
fisher
scientif
waltham
usa
proteas
inhibitor
cocktail
sigmaaldrich
western
blot
perform
previous
describ
slight
modif
chan
et
al
briefli
protein
separ
electrophoresi
sodium
dodecyl
sulfat
sd
gel
transfer
onto
polyvinyliden
difluorid
pvdf
membran
pvdf
membran
subsequ
block
bovin
serum
albumin
bsa
h
room
temperatur
incub
primari
antibodi
overnight
next
day
membran
wash
thrice
pb
tween
buffer
incub
peroxidaseconjug
secondari
antibodi
h
room
temperatur
protein
band
membran
visual
use
horseradish
peroxidas
hrp
substrat
biorad
hercul
ca
usa
antibodi
use
western
blot
studi
follow
antiakt
antibodi
abcam
antipanakt
phosphor
antibodi
abcam
goat
antirabbit
igg
h
l
secondari
antibodi
hrp
thermo
fisher
goat
antimous
igg
h
l
secondari
antibodi
hrp
thermo
fisher
akt
inhibitor
assay
cell
inocul
zikv
h
hpi
inoculum
remov
cell
wash
pb
dmem
contain
akt
inhibitor
dmso
ad
zikvinfect
cell
hpi
supernat
harvest
rlt
buffer
rna
extract
rna
tissu
mini
kit
qiagen
hilden
germani
viral
load
quantifi
qrtpcr
previous
describ
chan
et
al
chan
et
al
sirna
knockdown
assay
transfect
sirna
cell
perform
use
lipofectamin
rnaimax
thermo
fisher
scientif
previous
describ
slight
modif
chan
et
al
briefli
nm
akt
sirna
scrambl
sirna
mix
rnaimax
optimem
use
transfect
cell
h
posttransfect
sirna
differenti
viral
kinet
zikv
cell
without
hpi
zikvpr
rna
load
cultur
supernat
top
cell
lysat
bottom
sampl
consist
log
lower
dmsotreat
control
differ
time
point
hpi
experi
perform
triplic
three
independ
experi
confirm
denot
p
compar
dmso
control
group
correspond
time
point
student
ttest
data
present
mean
valu
standard
deviat
error
bar
abbrevi
dmso
dimethyl
sulfoxid
hpi
hour
postinocul
zikv
zika
viru
experi
perform
triplic
three
independ
experi
confirm
denot
p
denot
p
compar
dmso
control
group
student
ttest
data
present
mean
valu
standard
deviat
error
bar
abbrevi
dmso
dimethyl
sulfoxid
hpi
hour
postinocul
zikv
zika
viru
transfect
cell
inocul
zikv
h
hpi
inoculum
remov
cell
wash
pb
dmem
ad
cell
hpi
supernat
harvest
rlt
buffer
rna
extract
rna
tissu
mini
kit
qiagen
viral
rna
load
quantifi
qrtpcr
previous
describ
chan
et
al
chan
et
al
type
interferon
receptordefici
lethal
mous
model
zikv
infect
perform
previous
describ
slight
modif
dowal
et
al
guo
et
al
briefli
mice
mutant
mous
resourc
research
center
usa
randomli
divid
differ
group
receiv
treatment
sham
treatment
n
addit
group
uninfect
mice
receiv
intraperiton
oral
treatment
also
includ
control
tabl
mice
inocul
subcutan
plaqueform
unit
pfu
pb
zikvpr
anesthesia
day
postinfect
dpi
mous
receiv
dose
intraperiton
administ
mgkg
intraperiton
mgkg
oral
oral
gavag
suspend
pb
tween
sham
treatment
pb
hpi
hpi
previous
describ
tabl
chen
et
al
lee
et
al
mice
monitor
three
time
per
day
bodi
weight
chang
clinic
sign
diseas
previous
describ
dowal
et
al
six
sham
treatment
control
group
mice
group
euthan
weight
loss
weight
loss
clinic
sign
dpi
expect
day
death
untreat
control
mice
blood
organ
tissu
collect
viral
load
studi
previous
describ
chan
et
al
yuan
et
al
surviv
mice
monitor
dpi
data
analyz
graphpad
prism
softwar
graphpad
softwar
inc
previous
describ
chan
et
al
kaplanmei
surviv
curv
analyz
log
rank
test
weight
loss
compar
use
twoway
anova
student
ttest
use
determin
signific
differ
viral
load
tukeykram
post
hoc
test
use
discern
differ
among
group
p
consid
statist
signific
asianamerican
african
lineag
zikv
consid
pathogen
medic
import
musso
gubler
simonin
et
al
zhu
et
al
therefor
evalu
antivir
activ
zikv
strain
belong
lineag
viral
load
reduct
assay
inhibit
replic
zikv
strain
use
studi
includ
zikvpr
asianamerican
zikvgd
asianamerican
zikvu
african
cell
dosedepend
manner
fig
reduct
viral
rna
load
zikv
strain
log
cultur
supernat
cell
lysat
sampl
find
demonstr
could
inhibit
asianamerican
african
lineag
zikv
character
inhibit
zikv
prolong
incub
cell
infect
zikvpr
either
dmso
h
studi
differenti
viral
kinet
shown
fig
zikvpr
rna
load
cultur
supernat
cell
lysat
sampl
consist
log
lower
dmsotreat
control
multipl
time
point
hpi
cc
ic
select
index
cell
cultur
supernat
cell
lysat
respect
addit
inhibit
viral
replic
import
determin
cell
protect
effect
zikv
infect
present
cell
cell
viabil
assay
dosedepend
increas
percentag
viabl
cell
observ
cell
fig
mean
cell
viabil
increas
untreat
cell
approxim
cell
treat
suggest
provid
cell
protect
effect
zikv
infect
experi
perform
triplic
three
independ
experi
confirm
denot
p
denot
p
compar
dmso
control
group
student
ttest
data
present
mean
valu
standard
deviat
error
bar
abbrevi
zikv
zika
viru
major
clinic
manifest
zikv
infect
congenit
microcephali
meningoenceph
mainli
involv
neuron
cell
confirm
observ
viral
load
reduct
assay
use
cell
evalu
antivir
activ
epidem
zikvpr
strain
two
neuron
glioblastoma
cell
line
name
shown
fig
zikvpr
rna
load
significantli
reduc
p
cell
p
cc
ic
select
index
cell
respect
cell
respect
antivir
activ
zikv
confirm
even
high
moi
qrtpcr
plaqu
assay
fig
next
evalu
impact
antigen
express
zikvpr
neuron
cell
flow
cytometri
fig
remark
result
demonstr
significantli
inhibit
express
envelop
protein
fig
nonstructur
protein
fig
zikvpr
infect
cell
inhibit
evidenc
reduct
percentag
posit
cell
fig
well
reduct
mean
fluoresc
intens
fig
assess
vivo
antizikv
activ
infect
type
interferonreceptordefici
mice
zikvpr
treat
either
sham
treatment
zikvinfect
mice
treat
earli
infect
hpi
less
mean
bodi
weight
loss
fig
significantli
higher
surviv
rate
vs
p
fig
untreat
zikvinfect
control
moreov
mean
zikv
rna
load
blood
necropsi
tissu
mice
necropsi
gener
log
lower
untreat
mice
fig
also
evalu
regimen
delay
administr
either
intraperiton
oral
gavag
zikvinfect
mice
hpi
close
mimic
clinic
situat
virem
patient
receiv
treatment
immedi
infect
improv
clinic
virolog
paramet
obviou
mice
treat
oral
regimen
consist
much
higher
dose
mgkg
intraperiton
regimen
mgkg
fig
find
illustr
inhibit
zikv
vitro
also
vivo
especi
given
earli
high
dose
downregul
kda
glucoseregul
protein
akt
previous
propos
antidenv
mechan
chen
et
al
surprisingli
contrast
previou
report
find
downregul
fig
instead
found
substanti
downregul
phosphoryl
akt
protein
fig
regard
data
suggest
potenti
inhibit
zikv
replic
neg
regul
akt
signal
pathway
investig
akt
signal
pathway
modul
zikv
replic
treat
zikvinfect
cell
akt
inhibitor
akt
inhibitor
viii
previous
shown
inhibit
akt
activ
lindsley
et
al
interestingli
result
demonstr
zikv
replic
significantli
p
inhibit
presenc
akt
inhibitor
viii
fig
involv
akt
signal
pathway
zikv
replic
valid
sirna
knockdown
fig
akt
knockdown
result
signific
p
decreas
zikv
replic
agreement
result
akt
inhibitor
viii
experi
fig
taken
togeth
find
suggest
inhibit
zikv
replic
downregul
akt
signal
pathway
drug
compound
target
common
host
pathway
involv
replic
cycl
differ
virus
potenti
advantag
broadspectrum
antivir
zumla
et
al
especi
fig
inhibit
antigen
express
zikvpr
cell
cell
infect
zikvpr
moi
mockinfect
h
infect
cell
subsequ
treat
dmso
h
hpi
cell
harvest
immunolabel
flow
cytometri
analysi
express
level
zikv
envelop
protein
nonstructur
protein
b
label
mous
mous
respect
percentag
posit
cell
c
mean
fluoresc
intens
quantifi
experi
perform
triplic
three
independ
experi
confirm
denot
p
denot
p
compar
dmso
control
group
student
ttest
data
present
mean
valu
standard
deviat
error
bar
abbrevi
dmso
dimethyl
sulfoxid
hpi
hour
postinocul
mfi
mean
fluoresc
intens
nonstructur
protein
zikv
zika
viru
import
arbovirus
zikv
denv
chikungunya
viru
cocircul
geograph
region
andor
similar
clinic
featur
other
previous
identifi
number
clinic
approv
drug
novobiocin
lopinavirritonavir
ribavirin
sofosbuvir
antizikv
activ
vitro
andor
vivo
bullardfeibelman
et
al
kamiyama
et
al
yuan
et
al
repurpos
drug
directli
target
viru
inhibit
key
viral
enzym
viral
proteas
polymeras
may
antivir
activ
cocircul
arbovirus
structur
differ
viral
enzym
hosttarget
treatment
option
zikv
remain
scarc
previous
shown
vitro
vivo
antizikv
activ
recombin
interferon
side
effect
profil
may
limit
clinic
use
especi
pregnant
women
chan
et
al
chan
et
al
recent
studi
report
vitro
antizikv
activ
protein
kinas
inhibitor
endotheli
cell
astrocyt
anoth
recent
studi
report
activ
adenosin
monophosphateactiv
protein
kinas
small
molecul
activ
inhibit
zikv
replic
modul
host
cell
lipid
metabol
de
oya
et
al
find
support
hypothesi
drug
target
host
signal
pathway
may
use
treat
zikv
infect
cheng
et
al
prepar
work
kinas
inhibitor
recent
identifi
exhibit
vitro
antizikv
activ
human
osteosarcoma
cell
drug
screen
programm
rausch
et
al
howev
valid
preliminari
find
clinic
relev
cell
line
suitabl
anim
model
report
antizikv
mechan
investig
studi
demonstr
antizikv
activ
vitro
vivo
provid
novel
insight
drug
antizikv
mechan
first
show
inhibit
replic
zikv
belong
americanasian
african
lineag
import
lineag
zikv
consid
pathogen
human
moreov
treatment
provid
cell
protect
effect
zikvinduc
damag
antizikv
activ
valid
multipl
cell
type
includ
neuron
cell
clinic
relev
neurotrop
zikv
importantli
type
interferon
receptordefici
mice
treat
either
earli
delay
regimen
significantli
higher
surviv
rate
lower
viral
load
untreat
mice
suggest
antizikv
effect
present
vitro
also
lethal
anim
model
demonstr
inhibit
phosphoryl
akt
downstream
compon
tabl
six
sham
treatment
control
mice
group
euthan
weight
loss
weight
loss
clinic
sign
dpi
blood
organ
tissu
collect
zikv
rna
load
blood
copiesml
tissu
c
mice
determin
qrtpcr
bodi
weight
surviv
rate
mice
monitor
dpi
deatheuthanasia
result
combin
four
independ
experi
bodi
weight
trend
repres
surviv
mice
statist
signific
c
repres
differ
individu
treatment
group
sham
treatment
control
group
denot
pvalu
denot
pvalu
denot
pvalu
data
present
mean
valu
standard
deviat
error
bar
abbrevi
ip
intraperiton
pb
phosphatebuff
salin
po
per
os
zikv
zika
viru
akt
signal
pathway
promot
flaviviru
replic
counteract
virusinduc
cellular
apoptosi
zikv
rna
load
reduct
log
observ
cell
cultur
system
anim
model
treatment
compar
previou
find
antivir
effect
rna
virus
exampl
cc
ic
select
index
valu
hemorrhag
fever
virus
compar
find
zikv
mohr
et
al
flavivirus
log
reduct
denv
rna
load
ic
valu
denv
serotyp
vero
cell
hassandarvish
et
al
cc
higher
vero
cell
neuron
cell
suggest
select
index
flavivirus
may
even
higher
cell
type
hassandarvish
et
al
denvinfect
suckl
mice
treat
intracrani
intraperiton
log
reduct
infecti
viru
particl
plaqu
form
unit
brain
tissu
chen
et
al
comparison
virustarget
drug
often
achiev
higher
degre
viral
load
reduct
log
vitro
vivo
exampl
zikv
proteas
inhibitor
novobiocin
reduc
zikv
rna
load
log
vitro
vero
cell
blood
tissu
zikvinfect
mice
yuan
et
al
recent
describ
antivir
peptid
peptid
target
stem
region
zikv
envelop
protein
inhibit
viru
entri
host
cell
significantli
reduc
viral
rna
load
zikvinfect
interferon
receptordefici
mice
inhibit
vertic
transmiss
zikv
pregnant
mice
yu
et
al
find
unexpect
mice
receiv
one
dose
treatment
post
fig
inhibit
zikv
replic
via
downregul
akt
downregul
express
reduc
akt
phosphoryl
b
addit
akt
inhibitor
viii
c
significantli
reduc
zikv
rna
load
similarli
akt
sirna
use
studi
downregul
express
level
akt
pakt
significantli
reduc
zikv
rna
load
e
experi
perform
triplic
three
independ
experi
confirm
denot
p
denot
p
compar
dmso
scrambl
sirna
control
group
student
ttest
data
fig
e
present
mean
valu
standard
deviat
error
bar
abbrevi
akt
protein
kinas
b
dmso
dimethyl
sulfoxid
kda
glucoseregul
protein
nonstructur
protein
pakt
phosphoryl
protein
kinas
b
zikv
zika
viru
infect
antivir
mechan
via
downregul
signal
pathway
direct
virustarget
drug
advantag
broadspectrum
oral
avail
may
clinic
use
empir
therapi
laboratori
diagnosi
establish
patient
live
return
endem
area
arbovir
hemorrhag
fever
viral
diseas
develop
acut
febril
ill
effect
part
combin
treatment
regimen
consist
virustarget
hosttarget
drug
evalu
futur
studi
treatment
strategi
may
associ
improv
clinic
outcom
zikv
rna
viral
infect
hung
et
al
pire
de
mello
et
al
zumla
et
al
optim
deliveri
encapsul
drug
biodegrad
polymer
nanoparticl
reduc
cytotox
increas
drug
concentr
per
cell
may
facilit
use
clinic
set
hoang
et
al
jfwc
receiv
travel
grant
pfizer
corpor
hong
kong
astella
pharma
hong
kong
corpor
limit
invit
speaker
gilead
scienc
hong
kong
limit
luminex
corpor
author
declar
conflict
interest
fund
sourc
role
studi
design
data
collect
analysi
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
